30,900 Shares in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Purchased by ASR Vermogensbeheer N.V.

Key Points

• ASR Vermogensbeheer N.V. newly acquired 30,900 shares of Teva Pharmaceutical Industries Ltd., valued at approximately $475,000.
• Several institutional investors have recently increased their stakes in Teva, with 54.05% of the company's stock now held by institutional investors and hedge funds.
• Teva has seen recent upgrades in its stock ratings, with analysts giving it an average rating of "Buy" and a consensus target price of $24.71.

ASR Vermogensbeheer N.V. acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 30,900 shares of the company's stock, valued at approximately $475,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of TEVA. Golden State Wealth Management LLC acquired a new stake in Teva Pharmaceutical Industries during the first quarter worth about $39,000. New Age Alpha Advisors LLC bought a new stake in shares of Teva Pharmaceutical Industries during the first quarter valued at approximately $43,000. Marshall & Sterling Wealth Advisors Inc. acquired a new position in shares of Teva Pharmaceutical Industries during the fourth quarter worth approximately $44,000. Compagnie Lombard Odier SCmA acquired a new position in shares of Teva Pharmaceutical Industries during the first quarter worth approximately $54,000. Finally, Banque Cantonale Vaudoise bought a new position in Teva Pharmaceutical Industries in the 1st quarter worth approximately $74,000. Institutional investors and hedge funds own 54.05% of the company's stock.

Insider Buying and Selling at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 52,742 shares of the business's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $15.16, for a total value of $799,568.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP Matthew Shields sold 6,206 shares of the company's stock in a transaction that occurred on Tuesday, June 3rd. The stock was sold at an average price of $17.02, for a total transaction of $105,626.12. Following the transaction, the executive vice president owned 9,989 shares in the company, valued at $170,012.78. The trade was a 38.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 65,001 shares of company stock worth $996,958 over the last ninety days. Corporate insiders own 0.49% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently commented on TEVA. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the company from $21.00 to $23.00 in a research report on Monday, May 12th. UBS Group lowered their price objective on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a research note on Thursday, June 26th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Bank of America raised their price objective on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the company has an average rating of "Buy" and a consensus target price of $24.71.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $16.34 on Friday. The firm's 50-day moving average is $16.72 and its 200-day moving average is $16.39. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.77 and a current ratio of 1.06. The company has a market cap of $18.74 billion, a price-to-earnings ratio of -102.13, a PEG ratio of 0.97 and a beta of 0.62.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. The company had revenue of $4.18 billion for the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The business's revenue was up .3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS. Equities research analysts anticipate that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.